STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months

0:00-18:39

CEO Neil Warma describes ProMIS's approach of targeting amyloid beta oligomers as opposed to the plaques. He explains how so far they have avoided the ARIA (brain swelling) seen with other Alzheimer's treatments and discusses what the company hopes to see from this phase 1b study. Plus, comments on the recent failure of another company in this space.

Publisher

BiotechTV - News

Link

podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-ProMIS-Neurosciences-has-an-early--yet-important-Alzheimers-trial-scheduled-to-read-out-over-the-coming-months-e3s7s29

Published

November 11, 2026

Duration

19 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

BiotechTV

B-

BiotechTV - News

@biotechtvnews

#promisneurosciences #yetimportantalzheimers #comingmonths #lifesciences

The Nile